{"schema_version":"1","generated_at":"2026-11-11T04:48:24.010Z","data_as_of":null,"url":"https://www.findmykol.com/kol/prakash-ambady","json_url":"https://www.findmykol.com/kol/prakash-ambady/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"prakash-ambady","name":"Prakash Ambady","credential":"MD","specialty":"Neurology","specialty_raw":"Neurology","therapeutic_area":"Neurology","therapeutic_areas":["Neurology"],"city":"Portland","state":"OR","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1962784298","orcid":"0000-0003-4812-0581","openalex":"A5003425834"},"summary":"Prakash Ambady is a Neurology physician. OpenAlex indexes 104 publications with 1,626 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Neurology"]},"scholarship":{"works_count":104,"cited_by_count":1626,"h_index":17,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06175000","title":"Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Providence Health & Services","source_url":"https://clinicaltrials.gov/study/NCT06175000","trial_url":"https://www.findmykol.com/trial/NCT06175000"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":8,"shown":3,"withheld":5,"rows":[{"payer":"Jazz Pharmaceuticals","program_year":2025,"amount_usd":15643.4,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1962784298"},{"payer":"Telix Pharmaceuticals","program_year":2025,"amount_usd":164.53,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1962784298"},{"payer":"Elekta, Inc.","program_year":2025,"amount_usd":73.23,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1962784298"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1962784298","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":54.2,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":54.2,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":45.8,"classes_total":1,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":45.8,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Clinical Utility of [ 18 F]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma","year":2025,"journal":"American Journal of Neuroradiology","source_url":"https://doi.org/10.3174/ajnr.a9120","status":"verified"},{"title":"Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.2019","status":"verified"},{"title":"A pilot survey into the landscape of neuro-oncology care in the community","year":2025,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyaf047","status":"verified"},{"title":"ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.24.01034","status":"verified"},{"title":"Comparison of dynamic susceptibility contrast (DSC) using gadolinium and iron-based contrast agents in high-grade glioma at high-field MRI","year":2024,"journal":"The Neuroradiology Journal","source_url":"https://doi.org/10.1177/19714009241242596","status":"verified"}],"source":"works"},"contact":{"address_1":"9135 SW BARNES RD STE 461","city":"Portland","state":"OR","zip":"972256643","phone":"503-216-1150","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1962784298","source":"identity"},"similar":[{"name":"Bruce Miller","slug":"bruce-miller","institution":"University of California, San Francisco (UCSF)","specialty":"Neurology","url":"https://www.findmykol.com/kol/bruce-miller","json_url":"https://www.findmykol.com/kol/bruce-miller/profile.json"},{"name":"Brett Kissela","slug":"brett-kissela","institution":"Medical College of Wisconsin","specialty":"Neurology","url":"https://www.findmykol.com/kol/brett-kissela","json_url":"https://www.findmykol.com/kol/brett-kissela/profile.json"},{"name":"Richard Lipton","slug":"richard-lipton","institution":"Albert Einstein College of Medicine","specialty":"Neurology","url":"https://www.findmykol.com/kol/richard-lipton","json_url":"https://www.findmykol.com/kol/richard-lipton/profile.json"},{"name":"Bradley Boeve","slug":"bradley-boeve","institution":"Mayo Clinic","specialty":"Neurology","url":"https://www.findmykol.com/kol/bradley-boeve","json_url":"https://www.findmykol.com/kol/bradley-boeve/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":5,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-04-26","provider_certified":"2022-04-26","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}